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Background: The European Gaucher Alliance (EGA) was established in 1994 and constituted in 2008 as an umbrella
group supporting patient organisations for Gaucher disease. Every two years, the EGA conducts a questionnaire
survey of member associations to help develop its priorities and annual work programme. Results of the latest
survey are presented.
Methods: Between June 2012 and April 2013, the 36 members and associate members of the EGA were asked to
complete a questionnaire detailing membership numbers, disease specific treatments used by patients, means of
access to treatment, availability of treatment centres and home infusions, sources of support for patients with
Gaucher disease, patient organisations’ activities, collaborations, funding sources and any issues of concern.
Questionnaires completed in 2012 were revised in January 2013 and responses analysed between July and
September 2013.
Results: Thirty three members returned data on one or more questions. Findings identified inequalities in access to
treatment both within and between members’ countries. Three of 27 countries, for which data were available, relied
totally on humanitarian aid for treatment and 6% of untreated patients in 20 countries were untreated because of
funding issues, a situation many feared would worsen with deteriorating economic climates. Access to treatment
and reimbursement represented 45% of members’ concerns, while 35% related to access to specialist treatment
centres, home infusions and doctors with expertise in Gaucher disease. Member associations’ main activities centred
on patient support (59% of responses) and raising awareness of Gaucher disease and patients’ needs amongst the
medical community, government and healthcare decision makers and the general public (34% of responses).
Twenty one (78% of respondents) indicated they were the only source of help for Gaucher disease patients in their
country. For many, activities were constrained by funds; two members had no external funding source. Activities
were maximised through collaboration with other patient organisations and umbrella organisations for rare
diseases.
Conclusion: The survey provided a ‘snapshot’ of the situation for patients and families affected by Gaucher disease,
helping the EGA direct its activities into areas of greatest need.
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The European Gaucher Alliance (EGA) (www.eurogaucher.
org) was established in 1994 and constituted in 2008 as
an umbrella group supporting patient organisations for
Gaucher disease. It currently has 31 member associa-
tions in Europe (in 32 countries) and 8 associate mem-
bers in 7 countries beyond Europe, which assist patients
and families affected by Gaucher disease, a rare inher-
ited metabolic disorder characterised by deficiency in
the activity of the lysosomal enzyme glucocerebrosidase.
Deficiency in glucocerebrosidase results in the accu-
mulation of the enzyme’s major substrate, glucocerebro-
side, in the lysosomes of macrophages. These substrate
laden macrophages infiltrate the organs of the body
leading to widespread and progressive disease involving,
most commonly, the spleen, liver and bone, although the
lungs, lymphatic system, kidneys, heart, skin, and central
nervous system may also be involved [1,2]. Patients may
exhibit signs and symptoms that include progressive en-
largement of the spleen and liver with associated abdom-
inal distension, pain and organ dysfunction; fatigue due
to anaemia; gum and nosebleeds due to thrombocyto-
penia, coagulopathy and platelet dysfunction; increased
susceptibility to infections as a result of neutropenia and
impaired neutrophil function; neurological complications;
and a wide range of skeletal manifestations such as bone
pain, bone crises, bone remodelling abnormalities, osteo-
penia and osteoporosis, pathological fractures and osteo-
necrosis, which may lead to disability and the need for
orthopaedic intervention [3,4]. Children, in addition, may
exhibit growth retardation [5] and delayed pubertal
development [6].
Type 1 Gaucher disease is by far the most common
form of Gaucher disease affecting approximately one in
50,000 - 100,000 worldwide and one in 400 – 600 in the
Ashkenazi Jewish population [7] and is traditionally de-
fined by the absence of neurological symptoms, although
a diagnosis of type 1 disease may not exclude the devel-
opment of neurological symptoms later in life [8]. Type
1 Gaucher disease is highly heterogeneous in terms of
age of onset, organs affected and rate of disease progres-
sion [3] and is also associated with an increased risk of
cancer, especially haematological malignancies of B-cell
origin, such as multiple myeloma [9] and an increased
risk of Parkinson’s disease [10].
Neuronopathic forms of Gaucher disease affect appro-
ximately 6% of Gaucher disease patients. These include
type 2 (acute neuronopathic) disease, where disease usu-
ally presents in the first 6 months of life, is rapidly pro-
gressive and frequently results in death before the age of
two years, and type 3 (chronic neuronopathic disease)
where neurological disease generally presents later in
childhood and has slower progression than in type 2
disease [11].Treatment for patients with non-neuronopathic symp-
toms first became available in 1991 in the form of enzyme
replacement therapy (ERT), which aims to supplement
deficient glucocerebrosidase by the intravenous adminis-
tration of a functional glucocerebrosidase enzyme. The
first enzyme to be used in the treatment of patients with
Gaucher disease was mannose terminated human placen-
tal glucocerebrosidase, alglucerase (Ceredase®), which was
replaced in 1994 by its recombinant form, imiglucerase
(Cerezyme®), (both manufactured by Genzyme Corpor-
ation, Cambridge, MA, USA). A second ERT, velaglucer-
ase alfa (VPRIV®; Shire Human Genetic Therapies, Dublin,
Ireland) became available in 2010 and a third, taliglucerase
alfa (Elelyso®; Protalix, Carmiel, Israel) has become avail-
able in the USA (approved by the FDA in 2012), Israel (in
2012) and Brazil (in 2013).
An alternative treatment approach, substrate reduction
therapy (SRT) (miglustat [Zavesca®], Actelion Ltd, Basel,
Switzerland) aims to reduce the accumulation of gluco-
cerebroside by inhibiting its synthesis. This oral therapy
was licensed in 2002 for mildly affected adult Gaucher
patients for whom ERT is unsuitable [12]. An alternative
SRT eliglustat tartrate (Cerdelga™; Genzyme Corporation,
Cambridge, MA) for adult patients with type 1 Gaucher
disease is currently available to patients as part of clinical
trials [13]; decisions on marketing authorisation from the
FDA and EMA for eliglustat tartrate are expected in 2014.
Treatments can transform patients’ lives by amelio-
rating many of the signs and symptoms of non neuro-
nopathic disease [13-17], especially haematological and
visceral aspects of disease, but they do not represent a
cure for Gaucher disease; treatment is for life and in-
terrupted treatment may incur a risk of clinical regres-
sion [18,19]. Skeletal complications may persist in some
Gaucher disease patients despite treatment [20], and the
impact of treatment on the incidence of associated comor-
bidities is not well understood [10,21]. Current treatments
for Gaucher disease are also expensive (in the region,
depending the patient’s weight and dosing regimen, of
200,000 – 380,000 US Dollars/154,000 – 292,600 Euros
per patient per year), which creates significant challenges
for health care providers. There is no currently available
treatment that has any significant impact on the neuro-
logical manifestations of Gaucher disease [1]; the lack of
treatment to address neuronopathic disease represents a
major unmet need for affected patients.
As with many rare diseases, awareness of Gaucher dis-
ease amongst the medical community is low. Obtaining
an accurate diagnosis can be a prolonged process involv-
ing many medical specialities and sometimes incurring
unacceptable delays to appropriate medical care [22,23].
Individuals diagnosed with Gaucher disease may never
have heard of their condition before and it is common for
patients to have never met another affected individual.
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of information and support for affected families; in raising
awareness of the disease amongst the public and medical
community, which can promote early diagnosis [24]; in
defining and raising awareness of the specific issues that
patients affected by disease face, and in facilitating
research into the disease [25].
The principal roles of the EGA in supporting patient
organisations for Gaucher disease are to provide guid-
ance and encouragement to these groups, to communi-
cate the latest developments in understanding Gaucher
disease; to encourage research into Gaucher disease; to
work with healthcare professionals and scientists to
define priorities in the understanding of Gaucher disease
and its management; to represent the interests of Gaucher
patients to European and international organisations and
bodies; and to help ensure that appropriate treatment is
available to all Gaucher disease patients who need it.
Healthcare professionals and scientists play an important
role in supporting the work of patient groups and have in-
volved patient group representatives in scientific meetings
about Gaucher disease. Patient representatives were invited
to join the first meeting of European Working Group on
Gaucher disease (EWGGD) in 1994, and have continued
to take part in these meetings, which are held every two
years. During these events, EGA patient representatives
take time to discuss their own priorities and concerns. As
part of activities to prepare for these meetings and define
how to better support its members and develop its work
programme, the EGA conducts a questionnaire survey of
its member associations every two years to identify com-
mon areas of interest, priorities and concerns for patient
organisations and the Gaucher disease patients they
represent. The results of the latest survey prepared for the
2014 EWGGD meeting in Haifa, Israel, are outlined here.
Methods
Between June 2012 and April 2013, the 36 members and
associate members of the EGA (in Austria, Belgium,
Bosnia & Herzegovina, Bulgaria, Canada, Czech Republic,
Denmark, Estonia, Finland, France, Germany, Greece,
India, Israel, Italy, Jordan, Latvia, Lithuania, Macedonia,
Mexico (2 organisations), the Netherlands, Norway,
Poland, Romania, Russia, Serbia, Slovakia, Slovenia, South
Africa, Spain, Sweden, Switzerland, United Kingdom [UK]
& Republic of Ireland (RoI) (1 organisation), Ukraine and
United States of America [USA]) were asked to complete
a questionnaire detailing:
Association membership:
 Membership numbers and the proportion of
members that are patients with Gaucher disease
and/or family members The approximate number of all Gaucher patients in
the member organisation’s country (and if known,
the number of children under 18 and the number of
adults)
Treatment:
 Approximate numbers of patients receiving
treatment (and the treatment type)
 Approximate numbers of patients on a humanitarian
aid programme
 Approximate numbers of patients not receiving
treatment (and reasons, if known)
Healthcare:
 The names of main hospitals where Gaucher
patients may be treated
 Whether home infusions are available in the
member’s country
The patient organisation’s activities:
 The activities that the patient organisation offers
 Membership of other national/international
organisations
 Whether the patient association works with any
other organisations nationally on a regular basis
 How the patient association is funded
 Whether there is any other means of support for
patients with Gaucher disease in the member’s
country
 Any concerns that the patient organisation or its
members face in the member country
The questionnaires were completed between June 2012
and April 2013. Those completed in 2012 were revised in
January 2013. Responses were analysed between July and
September 2013.Consent
This survey was carried out with the voluntary partici-
pation of EGA member organisations. All member orga-
nisations’ representatives reviewed and agreed the final
manuscript before submission for publication. The study
questionnaire, which was prepared by and approved by
the EGA Board of Directors, did not ask for any identifi-
able personal details about participating organisations’
members or any identifiable details of their clinical
history, which required the consent of any specific indi-
vidual. The questionnaire and conduct of the survey
were compliant with the principles of the Declaration of
Helsinki.
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Of the EGA’s 36 member and associate member patient
organisations, 33 member organisations returned data
on one or more questions (Table 1). Of these 33 member
associations, 23 were specific to Gaucher disease (in
Austria, Bulgaria, Canada, Czech Republic, Denmark,
Estonia, Finland, German, Israel, Italy, Jordan, Lithuania,
Mexico [AGdM], Norway, Poland, Russia, Serbia,
Slovenia, Spain, Sweden, UK & RoI, Ukraine and USA);
ten associations had a wider remit and included, for
example, other lysosomal storage diseases (LSDs), other
rare diseases or metabolic diseases (Belgium, Bosnia
& Herzegovina, Greece, Latvia, Macedonia, Mexico
[PPuDM], the Netherlands, Romania, South Africa and
Switzerland). Three patient associations (from Croatia,
Paraguay and Moldova), which joined the EGA between
June and September 2013, are not included in the survey.Association membership
Of the 33 contributing patient associations, 28 (85%)
completed data on membership numbers, which totalled
approximately 3322 individuals (data not shown). Of the
28 contributing groups, 17 (61%) provided information
on the numbers of Gaucher patients in their member-
ship (as distinct from patients with other disorders, un-
affected relatives or other members). Of an approximate
total 1771 members in these 17 associations, approxi-
mately 918 (52%) were patients with Gaucher disease.
Of the 17 contributing groups, 13 (76%) were Gaucher
disease specific associations. Gaucher disease patients
represented 69% of overall membership in these organi-
sations (1204 members and 825 Gaucher disease pa-
tients) (Table 2).
The total number of Gaucher patients (in the 17
member associations that provided sufficient data) rep-
resented 45% of the estimated total numbers of Gaucher
disease patients in all their countries at the time of data
collection (Table 2). Percentages for individual countries
ranged from 100% (in Austria, Bosnia & Herzegovina,
and Denmark) to zero (in Latvia where parents of a child
with Gaucher disease were members of the patient asso-
ciation, but their child was not). The median value for
Gaucher disease patient membership was 75%.Treatment
Twenty seven member organisations contributed data
on treatments received by a total of 2043 patients in
their countries (not necessarily all members of contrib-
uting member associations). Of these, 1317 (64%) were
treated with imiglucerase ERT, 466 (23%) received vela-
glucerase alfa ERT, and 86 (4%) received taliglucerase
alfa ERT; 75 (4%) received miglustat SRT, 93 (5%) re-
ceived eliglustat tartrate SRT, and 6 (<1%) received othertreatments, such as alglucerase or an investigational
therapy in early stage clinical trials (Table 3).
A total of 66 patients received treatment as part of a
humanitarian aid programme; 20 (30%) were from
Ukraine (56% of all patients receiving treatment in the
country), 13 (20%) from Serbia (48% of treated patients
in the country), 16 (24%) from Jordan (100% of treated
patients), 5 (8%) from South Africa (9% of treated
patients), 4 (6%) from Macedonia (100% of treated
patients), 4 (6%) from Bosnia & Herzegovina (100% of
treated patients), and 1 (2%) from Latvia (50% of treated
patients). In summary, 100% of patients received their
treatment through humanitarian aid in 3 countries; 40 -
60% of patients received treatment through humanitarian
aid in four countries and less than 10% of patients re-
ceived treatment though humanitarian aid in one country
(Table 4).
Twenty associations returned information on untrea-
ted patients. These totalled 720 individuals, 611 (85%) of
whom were untreated because their clinical condition
did not warrant or qualify for treatment; 46 (6%) were
untreated because of lack of funding; 50 (7%) for whom
no specific reasons were cited, and 13 (2%) who were
untreated through personal choice (Table 5).
Healthcare
Thirty one patient groups provided information on the
number of main hospitals where patients with Gaucher
disease are treated (Table 6). Overall, no main treatment
centres were specified by 2 of 31 (6%) respondents (from
Lithuania and Switzerland). In Lithuania, patients were
treated in local hospitals and in Switzerland it was stated
that patients can be treated anywhere as long as provi-
ders can provide evidence that they have been adequately
trained to administer treatment (trained in preparation,
intravenous infusion care and anaphylactic shock manage-
ment). Five respondents (16%) reported one main treat-
ment hospital; 14 (45%) reported 2–5 main hospitals, 6
(19%) have 6–10 main treatment hospitals and 4 (13%)
have 11 or more main hospitals. Thirty two member asso-
ciations reported on the availability of home infusions for
enzyme replacement therapy. Home infusions were stated
to be available in 20 of 33 (61%) countries (RoI counted
separately in this case as policy on home infusion differs
between the UK and RoI) (Table 6).
The patient organisations’ activities
Thirty one associations provided 103 responses to de-
scribe their activities. The responses were categorised as
shown in Figure 1. The activities undertaken by organi-
sations, varied considerably; 59% of all activities were
directly related to providing support to patients and pro-
moting contact between patients, organising events for
patients, disseminating information to Gaucher patients
Table 1 Contributing EGA member organisations
Country Organisation Scope
Austria Österreichische Gaucher Gesellschaft/Austrian Gauchers Association Gaucher disease
Belgium Belgische Organisatie voor Kinderen en Volwassesn met en Stofwisselingsziekte/Belgian
Association for Metabolic Diseases
Metabolic diseases
Bosnia & Herzegovina Udruženje oboljelih od rijetkih bolesti u Bosni i Hercegovini/Association of people with rare
diseases in Bosnia & Herzegovina
Rare diseases
Bulgaria Национална Асоциация на Болните от Гоше/National Association of Gaucher patients in
Bulgaria
Gaucher disease
Canada National Gaucher Foundation of Canada Gaucher disease
Czech Republic Občanské sdružení rodičů dětí a dospělých postižených Gaucherovou chorobou/Czech
Gaucher Association
Gaucher disease
Denmark Gaucher Foreningen i Danmark/Gaucher Association Denmark Gaucher disease
Estonia Gaucher Eesti MTÜ/Estonian Gaucher Association Gaucher disease
Finland Suomen Gaucher Yhdistys/Finnish Gaucher Association Gaucher disease
Germany Gaucher Gesellschaft Deutschland/German Gaucher Association Gaucher disease
Greece Πανελλήνιος Σύλλογος Ασθενών & Φίλων Πασχόντων από λυσοσωμικά Νοσήματα ‘Η
Αλληλεγγύη’/Patients and friends of those suffering from lysosomal storage disorders ‘The
Solidarity’
LSDs
Israel Israeli Gaucher Association/ העמותההישראליתלגושה Gaucher disease
Italy Associazione Italiana Gaucher/Italian Gaucher Association Gaucher disease
Jordan Jordanian Gaucher Association/ ﺟﻢﻉﻳﺔﺍﻝﻉﻧﺎﻱﺓﺏﻣﺮﺿﻰﻏﻮﺵﻳﻪﺍﻝﺥﻳﺮﻱﺓﺍﻷﺭﺩﻥﻳﺔ Gaucher disease
Latvia Reto slimību biedrība “Caladrius”/Society of Rare Diseases Caladrius Rare diseases
Lithuania Lietuvos Gošė Asociacija/Lithuania Gaucher Association Gaucher disease
Macedonia Здружение на граѓани за ретки болести “Живот со Предизвици” – Битола/Association of
citizens for rare diseases - Life with Challenges
Rare diseases
Mexico Asociacion Gaucher de Mexico/Gaucher Association of Mexico Gaucher disease
Mexico Proyecto Pide un Deseo México, i.a.p./Make a Wish Project LSDs
The Netherlands VKS – Diagnosegroep Gaucher/Gaucher Diagnosis Group Metabolic diseases
Norway Gaucher Foreningen Norge/Gaucher Association Norway Gaucher disease
Poland Stowarzyszenie Rodzin z Chorobą Gauchera/Association of Families with Gaucher disease Gaucher disease
Romania Fundatia Romana Pentru Bolile Lizozomale/Romanian Foundation for Lysosomal Diseases LSDs
Russia Межрегиональная общественная организация «Содействие инвалидам с детства,
страдающим болезнью Гоше и их семьям»/Interregional non-government organization
“Assistance to invalids suffering from Gaucher disease and their families”
Gaucher disease
Serbia Udruženje gradjana za pomoć u lečenju obolelih od Gošeove bolesti (UGOŠ)/Association for
help in treatment of patients suffering from Gaucher’s disease
Gaucher disease
Slovenia Društvo bolnikov z gaucherjevo boleznijo Slovenije/Slovenian Gaucher Association Gaucher disease
South Africa The Gaucher and LSD Society of South Africa Gaucher disease/LSDs
Spain Asociación Española de Enfermos y Familiares de la Enfermedad de Gaucher/Spanish
association of Gaucher patients and their relatives
Gaucher disease
Sweden Morbus Gaucherföreningen i Sverige/Swedish Gaucher Disease Association Gaucher disease
Switzerland Vaincre les Maladies Lysosomales – Suisse/Swiss Association for Overcoming Lysosomal
Storage Disorders
LSDs
UK & Republic of Ireland (RoI) The Gauchers Association Gaucher disease
Ukraine Всеукраїнська громадська організація “Об”єднання інвалідів-хворих на хворобу
Гоше/All-Ukrainian Gaucher Association
Gaucher disease
USA National Gaucher Foundation Gaucher disease
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as % of patients
in country
Austria 40 20 50 20 2 18 100
Bosnia & Herzegovina 237 4 2 4 0 4 100
Denmark 32 17 53 17 5 12 100
Estonia 4 3 75 4 0 4 75
Finland 15 4 27 10 2 8 40
Germany 210 155 74 335 35 300 46
Greece 200 79 40 80 10 70 99
Israel 500 350 70 850 300 550 41
Italy 114 114 100 240 0 240 48
Jordan 30 10 33 28 19 9 36
Latvia 30 0** 0 3 1 2 0
Lithuania 9 7 78 8 2 6 88
Macedonia 100 10 10 12 6 6 83
Serbia 35 28 80 36 7 29 78
Slovenia 37 17 46 19 2 17 89
Spain 110 60 55 300 100 200 20
Sweden 68 40 59 55 10 45 73
TOTAL 1771 918 52 2021 501 1520 45
GD: Gaucher disease; *Only member organisations providing complete data (17 respondents); **The parents of child with GD are members; child is not a member;
Italics: Associations for GD + other diseases. Not in italics: GD specific associations (n = 13).
GD patients represented 52% of overall membership in responding patient organisations (918 GD patients of 1771 total members).
GD patients represented 69% of overall membership in GD specific organisations (825 GD patients of 1204 total members).
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social rehabilitation, 34% of activities were related to
raising awareness of Gaucher disease and the issues that
patients face amongst the medical community, the wider
(non-Gaucher) community, with government, and with
the pharmaceutical industry; 7% of activities were related
to rare disease strategy and research into Gaucher disease.
Other sources of support for Gaucher patients
Of 27 members who responded, 21 (78%) indicated that
they were the only source of support for Gaucher
patients in their countries (Belgium, Canada, Denmark,
Germany, Greece, Israel, Italy, Jordan, Latvia, Lithuania,
Macedonia, the Netherlands, Norway, Poland, Romania,
Russia, Serbia, Slovenia, Sweden, UK & RoI, and Ukraine).
Six member associations (22%) indicated other sources
of support for patients. These included support available
through rare disease organisations (Austria, Bulgaria,
Mexico, South Africa, Spain, and USA) and two (Spain,
and the USA) referred to other Gaucher disease specific
patient organisations, such as the Spanish Federation of
Gaucher patients and, in the USA, the Children’s Gaucher
Research Fund, an organisation supporting research into
type 2 and type 3 Gaucher disease, but which may alsohelp families by putting them in touch with each other.
The member from the USA also mentioned that there was
a financial assistance programme available to Gaucher
patients.
Membership of other national/international organisations
Twenty five member associations completed the question
on membership of other national/international organisa-
tions. Of these 25 associations: 18 (72% of organisations)
were members of national or international rare disease
organisations (such as EURORDIS, NORD); 1 (4%) was a
member of another Gaucher disease-related organisation
(excluding the EGA), 6 (24%) were members of other
patient organisations (not Gaucher disease related) and 2
(10%) were members of other national or international
bodies, such as a health care coalition and a genetic
counselling organisation. Five (20%) did not belong to
any other organisation.
Work with nationally
Twenty eight members responded to the question about
whether they worked with any other organisations na-
tionally on a regular basis: 5 associations (18%) (Latvia,
Lithuania, Mexico AGdM, Poland, Ukraine) did not
Table 3 Numbers of patients receiving Gaucher disease specific treatments
Member association’s country Imiglucerase Velaglucerase alfa Eliglustat tartrate Miglustat Taliglucerase alfa Other* Total
Austria 11 5 4 1 21
Belgium 22 3 1 26
Bosnia & Herzegovina 3 1 0 4
Bulgaria 13 13
Canada 60 13 13 11 2 99
Czech Republic 21 6 2 29
Denmark 11 5 16
Estonia 3 3
Finland 6 2 1 9
Germany 230 61 9 1 301
Greece 57 6 3 6 72
Israel 80 160 10 60 5 315
Italy 113 35 10 158




Norway 5 8 13
Romania 55 1 2 58
Russia 258 6 40 304
Serbia 13 6 8 27
Slovenia 13 4 17
South Africa 48 3 5 56
Spain 80 50 4 30 5 169
Sweden 37 6 3 46
UK & RoI 112 93 2 7 5 1 220
Ukraine 36 36
TOTAL 1317 466 93 75 86 6 2043
% of total 64 23 5 4 4 0.3
*Other treatments: Israel: oral enzyme replacement therapy (PRX-112) in clinical trial [Protalix, Carmiel, Israel], UK & RoI: 1 alglucerase.
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other organisations on an occasional basis. Latvia, for
example, reported a collaboration with the Latvian Hae-
mophilia Association for Rare Disease Day and Lithuania,
as a relatively new society, has yet to establish regular
working relationships; 23 members (82%) (from Austria,
Belgium, Bosnia & Herzegovina, Canada, Denmark,
Finland, Germany, Greece, Italy, Jordan, Macedonia,
Mexico PPuDM, the Netherlands, Romania, Russia,
Serbia, Slovenia, South Africa, Spain, Sweden, Switzerland,
UK & RoI, and USA) provided information on their,
often multiple, collaborations. Fifteen of the respond-
ing 28 member organisations (54%) indicated that they
collaborated with pharmaceutical companies, 12 (43%)
worked with rare disease organisations, 11 (40%) worked
with other patient organisations, 6 (21%) worked withtreatment centres and the medical community; 4 (14%)
worked with other organisations such as the media,
non-pharmaceutical companies, and youth councils, and 3
(11%) worked with government.
Funding
Thirty members provided information about sources of
funding for their patient organisations. Two (7%) (Jordan
and Ukraine) reported that they had no source of external
funds. Eighteen of the respondents (60%) cited a variety of
subsidies, grants and miscellaneous donations that in-
cluded, for example, lottery money (Denmark), donations
from health insurance fund (Germany), income tax sub-
sidies (Lithuania, Romania), a governmental small subsidy
for volunteers helping in the patient organisation and
subsidies from various cities (Belgium) and grants and
Table 4 Number of Gaucher disease patients receiving









Bosnia & Herzegovina 4 4 100
Jordan 16 16 100
Latvia 1 2 50
Lithuania 3 8 38
Macedonia 4 4 100
Serbia 13 27 48
South Africa 5 56 9
Ukraine 20 36 56
Total 66 153 43
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ganisations (Bosnia & Herzegovina, Canada, Greece,
Latvia, Serbia, Slovenia, Switzerland, USA). Pharma-
ceutical companies provided support to 15 patient or-
ganisations (50% of respondents), either on an annual
basis and/or in response to requests for unrestricted




























Serbia 9 3 6
Slovenia 2 2
South Africa 20 20




Total 720 13 611 46 50
% of total 2 85 6 7associations (20%) raised funds through membership
fees for patients and families (Belgium, Germany, Poland,
Serbia, Spain, Switzerland) and six (20%) held fund raising
events such as sponsored runs, family days, concerts and
family events (Belgium, Latvia, the Netherlands, South
Africa, UK & RoI, and the USA).
Concerns expressed by patient organisations
Twenty seven members outlined the issues their associ-
ation and Gaucher patients face. Fifty five points of con-
cern were raised. Of these 25 (45%) related to access to
Gaucher specific treatment, 19 (35%) were related to the
medical care received by patients; 5 (9%) related to the
difficulties faced by Gaucher patients in their everyday
lives, and 6 (11%) were issues related to the management
and future of patient organisations (Table 7).
Discussion
This survey provides a ‘snapshot’ of the activities, inter-
ests and issues of concern of 33 EGA member associa-
tions between January 2013 and April 2013.
Patients with Gaucher disease are relatively fortunate
amongst sufferers of rare diseases in that there are mul-
tiple disease-specific treatments available to them able to
address some of the non neuronopathic aspects of dis-
ease. Data from 27 member associations suggested that
the longest established treatment, imiglucerase ERT, was
by far the most widely used treatment (64% of treated
patients) followed by velaglucerase alfa ERT (23%),
eliglustat tartrate SRT (5%), taliglucerase alfa ERT (4%),
and miglustat SRT (4%) (Table 3). Some patients, how-
ever, remain untreated. For 720 patients for whom a rea-
son for lack of treatment was known, approximately 85%
(611 patients) were untreated because of clinical reasons,
i.e. that their disease did not warrant treatment. Eighty
eight per cent of these individuals came from Israel where
Gaucher disease is relatively common [26] and where
there is a high frequency of the N370S/N370S genotype,
which is associated with a milder, later onset phenotype
(although not exclusively) [27]. Forty six patients (6%)
were reported to be untreated because of funding issues
(Table 5).
Access to treatment accounted for almost 50% of con-
cerns raised by member organisations and highlighted
inequalities both within and between countries. Canada’s
10 provinces and three territories, for example, each
have different health care policies and depending on
where patients live, they may or not have access to reim-
bursement for treatment. Respondents reported that there
is no funding for the treatment of Gaucher disease in
Jordan, and no funding for adult patients in Latvia
and Ukraine. While there is a programme for funding
treatments for rare diseases in Macedonia, none of
Macedonia’s four treated Gaucher patients received funding
Table 6 Number of main hospitals where Gaucher patients are treated and availability of home infusions
Number of
main hospitals
Member association’s country Home infusions available Home infusions
not available
None Lithuania, Switzerland Switzerland Lithuania
1 main hospital Czech Republic, Estonia, Macedonia,
the Netherlands, Ukraine
The Netherlands Czech Republic, Estonia,
Macedonia, Ukraine
2-5 main hospitals Bosnia & Herzegovina, Bulgaria, Denmark,
Finland, Israel, Jordan, Latvia, Norway,
Russia, Serbia, Slovenia, South Africa, Spain,
Sweden
Bosnia & Herzegovina, Bulgaria, Denmark,
Finland, Israel, Norway, Russia, Slovenia,
South Africa, Spain, Sweden
Jordan, Latvia, Serbia
6-10 main hospitals Belgium, Germany, Greece, Italy,
Romania, UK & RoI
Germany, Italy, Romania, UK Belgium, Greece, RoI
11 or more main hospitals Austria, Canada, Poland, USA Austria, Canada, USA Mexico, Poland
31 respondents 32 respondents covering 33 countries (UK and RoI counted separately as policy
on home infusion differs)
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patients in Bosnia & Herzegovina, Jordan, and Macedonia
were reliant on humanitarian aid (Table 4). Concerns were
raised that worsening economies in many countries might
result in pharmaceutical companies being unable to con-
tinue supporting humanitarian aid programmes to the
same extent.Figure 1 Member associations’ activities.Even where treatment for Gaucher disease is available
through national and private funding schemes, fears
were expressed that access to treatment might not be
maintained in the future for budgetary or other reasons.
The Swiss Gaucher patients association cited the case
of the withdrawal of reimbursement by all insurance
companies in Switzerland for late-onset Pompe disease
Žnidar et al. Orphanet Journal of Rare Diseases 2014, 9:134 Page 10 of 14
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a reassessment of the therapy’s clinical efficacy [28]. While
the respondent pointed out that treatment for Gaucher
disease has a stronger evidence base regarding outcomes,
it highlights inequality of access to treatment in different
countries for rare disease and demonstrated how patients’
treatment options can be suddenly limited as a result of
changing healthcare policies. Further examples include
the withdrawal of the exemption for Gaucher disease from
cost effectiveness assessment in Sweden due to high price,
and discussions in the Netherlands on whether treatment
for Fabry disease and Pompe disease should be fully
reimbursed [29].
Concerns for the on-going availability of treatments
and the funding of new treatment for rare diseases have
also been raised in the UK following the transfer of
the assessment for medicines for very rare disease
from the Advisory Group for National Specialised Services
(AGNSS) to the National Institute for Health and Clinical
Excellence (NICE) in April 2013. Fears have been ex-
pressed that NICE may struggle to reconcile the high cost
of some treatments for very rare disease with its funding
thresholds [30]. A recent study using the UK as a model,
presents compelling legal arguments (involving disability
legislation, national and organisational constitutions,
judicial review, tort law and human rights legislation) for
the continued provision of treatment for orphan diseases
despite economic pressure to reduce funding, and which
may be applicable across the EU in negotiating national
reimbursement guidelines [29].
Several members indicated that budget constraints
were making treatment harder to obtain incurring delays
in treatment and treatment initiation, and resulting in
treatment at low doses even in patients with established
disease (Norway, Romania, Spain). Treatment at lower
doses was also, in part, a persisting consequence of the
recent shortage in imiglucerase and the consequent
sharing of available enzyme supplies amongst patients
[31]. Although patients in some countries were able to
switch to an alternative therapy to maintain treatment,
others were unable to do so because alternative treat-
ments had not been approved for marketing in their
country. As requests for marketing authorisations have
to be initiated by pharmaceutical companies it was felt
that there might not be sufficient financial incentive for
companies to enter the market in countries with few
patients. The concern was also expressed that low dose
treatment may become the norm regardless of drug
supplies. The question of optimal enzyme dose regimens
for Gaucher patients is a topic of discussion [32-34] but
it has been recommended by clinical experts in Gaucher
disease, that treatment should be tailored to patient’s
needs [35]. Dose decisions, therefore, should be the
domain of the treating clinicians, and not dictated byinflexible administrative policies. While initial reports
during the imiglucerase shortage tend to suggest that
drug reduction did not induce substantial changes in
clinical laboratory results, it did appear to influence
feelings of well-being of some Gaucher patients [36]. As
reported by the Italian respondent, many patients were
reluctant to switch to new therapies because their doc-
tors were reticent and had limited knowledge of alter-
native therapies, which may have influenced patients’
perceptions.
Respondents also raised concern over the way that the
imiglucerase shortage was managed in some regions and
that there were vast differences in practice amongst
treating hospitals. Anecdotal reports from respondents
suggested that treatment had been withheld during the
shortage in some centres in some countries despite the
availability of low dose treatment for all, or administered
at even lower doses than had been made available for
patients. In contrast, the shortage was reported to have
been managed well in other centres with enzyme
supplies being allocated to patients based on a rational
assessment of each patient’s clinical need by the doctor
in charge.
As well as differences in access to treatment for Gaucher
disease, standards of healthcare for Gaucher patients in
respondents’ countries varied (accounting for 35% of re-
sponses on concerns). In common with a previous report
on healthcare for patients with rare disease, Gaucher
patients may have problems accessing good quality health
care services [24]. Seven member associations’ representa-
tives (26% of respondents) felt that knowledge about
Gaucher disease amongst the general medical community
in their country was inadequate (Table 7) making it diffi-
cult for patients to obtain information about their disease.
This lack of awareness and lack of knowledge may result
in delayed diagnosis as reported earlier [22]. Four member
associations referred to a lack of Gaucher disease expertise
in their countries (Finland, Mexico, Lithuania, Slovenia).
For example, in Lithuania, it was reported that there was
only one doctor (a paediatrician) with specialist knowledge
of Gaucher disease, and that this doctor could not be
accessed by adults through the healthcare system, and in
Slovenia, there were no rare disease reference centres and
a lack of specialists, such as radiologists, well experienced
in Gaucher disease.
Although the questionnaire survey identified the num-
ber of main hospital where Gaucher patients may be
treated in member association countries, it was not clear
in all cases, which ones were designated, or recognised,
centres of expertise or whether the main hospitals of-
fered specialist expertise in the management of Gaucher
disease. As reported by the Swiss respondent, not all
main hospitals have a Gaucher disease specialist on site.
While a number of designation criteria for national




Medical care (Total 19 responses from 12 member associations)
Lack of information/limited knowledge among healthcare professionals/
lack of Gaucher disease specialists
7 Finland, Latvia, Lithuania, Macedonia,
Mexico PPuDm, Slovenia, Switzerland
Lack of consensus on management approach for Gaucher disease 2 Slovenia, Switzerland
Unmet needs: neuronopathic Gaucher disease, bone, mental health services/
psycho-social support for patients
3 Slovenia, UK & RoI, USA
Lack of information on new therapies 1 Germany
Need for home infusions 1 Mexico PPuDM
Need for diagnostic centre/issues with delayed diagnosis/finding undiagnosed
patients, need for specialist centre
4 Mexico AGdM, Slovenia, USA, Russia
Lack of a national Gaucher disease registry 1 Slovenia
Access to treatment (Total 25 responses from 20 associations)
Treatment access/inequalities in access 9 Bosnia & Herzegovina, Canada, Greece, Jordan,
Latvia, Mexico PPuDM, Serbia, South Africa
Low treatment doses and delayed time to treatment 3 Norway, Romania, Spain
Imiglucerase shortage/way shortage was managed 4 Italy, Poland, South Africa, Spain
Changing economic environments/concerns for future reimbursement/
specialised services
7 Denmark, the Netherlands, Spain, Sweden,
Switzerland, UK & RoI, USA
Lack of collaboration with pharmaceutical companies regarding humanitarian aid 1 Jordan
Lack of dialogue with administrative authorities/hospitals/payers 1 Poland
Living with Gaucher disease (Total 5 responses from 5 associations)
Difficulties for Gaucher disease patients in finding jobs 1 Bosnia & Herzegovina
Patients’ fear of repercussions if disease is known for insurance/barrier to diagnosis 1 USA
Obtaining disability status for patients 1 Russia
Lack of information on Gaucher disease for the general public 2 Macedonia, Switzerland
Patient organisations (Total 6 responses from 5 associations)
Lack of Gaucher disease patient interest in patient organisation 3 Belgium, Germany, Slovenia
Need to collaborate (between patient organisations) 1 Mexico PPuDM
Changing financial situation and lack of funds to support patients 1 USA
Lack of umbrella organisation for rare diseases 1 Slovenia
A total of 27 member associations responded (55 responses).
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were defined in 2006 [37] and quality criteria defined in
2011 [38], designation criteria for centres of expertise vary
between countries and sometimes between regions and
may depend on the county’s policy for rare disease. Only a
few member states have officially designated centres of ex-
pertise for rare diseases financed by the relevant health au-
thorities (Denmark, Norway, Spain and the UK). Italy has
regionally designated centres. Some countries have non-
designated centres of expertise for rare diseases, which
may be acknowledged by some authorities, while some are
recognised only by reputation, and some are self-declared
centres of expertise [39]. A number of European countries
plan to elaborate designation procedures for centres of
expertise for rare diseases in the future, mostly within the
scope of a national plan/strategy for rare diseases. TheEuropean Commission recommended, that all member
states adopt a national plan or strategy for rare disease by
2013 [40].
Home infusions were not an option for patients living
in 13 countries (Table 6). While it might be expected
that home infusion would be available in countries with
restricted numbers of hospitals where patients may re-
ceive treatment for Gaucher disease, this did not appear
to be the case (Table 6). While not all patients may feel
comfortable with the concept of receiving treatment
away from a medical environment, time spent travelling
to treatment centres can have an impact on work, edu-
cation, finances and quality of life [41,42]. Home treat-
ment may offer a more convenient alternative and for
some may represent the only practical way of receiving
treatment when distances to treatment centres are great.
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patients receiving treatment through humanitarian aid at
their local hospital had to stop treatment because the
donor pharmaceutical company would no longer allow
infusions in the hospital (reason unspecified). Home in-
fusions although once available were no longer offered.
In order to continue treatment the patients had to take
time away from work every fortnight to travel to Serbia’s
treatment centre in Belgrade. As well as the time, cost
and inconvenience involved, absence from work on a
regular basis may mean that patients have to inform
employers of their health status and, as the Serbian
respondent reported, many may not wish to disclose this
information.
Three respondents highlighted the lack of adequate
mental health provision for Gaucher disease patients. As
with any patient suffering from a chronic medical
condition, patients with Gaucher disease may experience
psycho-social complications [43]. Specific concerns for
Gaucher disease patients include a difficulty coping with
diagnosis, dealing with the effects of pain and fatigue on
job, career, and recreational activities, difficulties with
social life, emotional problems such as depression, and
psychological distress [42].
Over 80% of responding member associations indi-
cated that they were the only source of help for Gaucher
patients and their families in their country. The main ac-
tivities of member associations were centred on patient
support (59% of responses), which included helping indi-
vidual patients, promoting and facilitating contact be-
tween patients in similar situations, holding patient and
family meetings, events and workshops, and providing
information on Gaucher disease and its treatment and
other services, such as help with social rehabilitation,
work, and benefits (for example, disability benefit) where
available. Several associations reported producing and
disseminating information about Gaucher disease and
new developments relating to Gaucher disease through
websites, newsletters and other publications, such as
leaflets and booklets. Activities also included guiding pa-
tients through any concerns associated with treatment,
helping patients in their interaction with doctors, medical
and administrative authorities, advising individuals on
where to go to for diagnosis if they suspected Gaucher
disease, help with hospital admissions, help in obtaining
access to treatment and helping patients learn about the
health economic system in their country.
Over one third of patient association activities related
to raising awareness of Gaucher disease in the medical
community or amongst the general public (including
government and health care decision makers). Twelve
member associations reported an active role in cooperat-
ing with government to raise awareness and educate
about rare disease, to inform government of specificneeds and gaps in the law for patients with a rare disease,
to defend the right of patients with rare disease and to
negotiate with government and insurance funders for
treatment reimbursement. Ukraine for example, has been
active in lobbying the President of Ukraine, the Supreme
Council of Ukraine, the Health Protection Ministry, to
request an increase public financing for children with rare
diseases and to develop the programme of public finan-
cing for adult patients; and Bosnia & Herzegovina, Latvia,
Macedonia, and Poland reported participating actively in
the development of national plans for rare diseases.
One specific problem identified by the respondent
from Macedonia was the lack of educational materials in
the local language, which severely hampered increasing
awareness of Gaucher disease. From the patient perspec-
tive it meant that patients had no materials to give to
members of the medical profession, to employers, tea-
chers or members of their own family who might need
to be informed about Gaucher disease. Similarly, lack of
written material made it difficult to deal with govern-
ment and to raise awareness among the general public.
The scale of activities undertaken by each member
organisation are inevitably influenced by the financial
resources available to them but even the two member
patient organisation without external funding resources
(Jordan and Ukraine) were able to provide support and
information to patients and provide a point of contact
for patients and families wishing to talk to each other, to
lobby government for increased funding for patients
with rare diseases (Ukraine) and to raise awareness of
rare diseases, help in obtaining a diagnoses for people
affected by Gaucher disease, and work with hospital and
doctors (Jordan). Although not explicitly stated by all,
these activities rely on the willingness of association
organisers to donate their time, and often their personal
money, to support any expenditure.
The single greatest specified external source of funding
was the pharmaceutical industry, although some associa-
tions exploited other resources such as lottery funds,
subsidies supported by income tax refunds (gift aid
schemes), and unspecified donations. Some associations
charged membership fees and funds were also raised
through fund raising events, which can help source
funds from outside the organisation. The respondent
from the USA pointed out that funding has become
more difficult ‘because of the economy and cutbacks
from the pharmaceutical industry’. Without proper
funding, it was stated that programmes may have to be
reduced.
To help maximise financial resources and to gain benefit
from the experience of other, possibly larger and longer
established and more experienced patient organisations,
some member associations collaborated with others na-
tionally and internationally. Umbrella organisations, such
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resource of advice, expertise and support.
Increasing membership of patient associations can
help to drive activities in supporting patients and fam-
ilies but three member organisations expressed concern
over the few patients and families joining patient organi-
sations in their countries and/or their reluctance to
become involved in activities. This, as suggested by the
Belgian respondent, may be partly because most patients
have access to treatment, feel well, and do not perceive a
need to belong to a patient organisation. This, however,
ignores the on-going difficulties of some patients, wher-
ever in the world they are located, that do not have
adequate treatment available to them (patients with neu-
ronopathic disease or patients who cannot gain funding
for treatment) and those who do not have access to
adequate healthcare services.Conclusions
Although there are several limitations in the conduct of
this survey in that not all patient organisations answered
all questions, different patient organisations may have
interpreted question differently and provided varying
levels of detail or approximations in their responses, the
survey revealed some insights into the priorities and
needs of Gaucher patient organisations and of the pa-
tients they represent. A key priority is to work towards
equitable access to treatment and equitable standards of
healthcare. Another important and related need is to in-
crease awareness of Gaucher disease, its manifestations
and impact on patients’ lives, amongst the medical com-
munity and amongst reimbursement agencies. Of grow-
ing concern is the worsening economic climate in many
countries, which creates unease for the future funding of
treatments for Gaucher disease and other rare diseases,
and also for the future maintenance of patient organisa-
tions’ activities.
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